Biotech Stock Picking for Charity - 2005 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2005

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Extra Pale who wrote (198)	9/27/2005 11:25:57 AM
From: Icebrg	Read Replies (1) of 322

The company wrote: A pooled analysis of XYOTAX treated patients from STELLAR 3, STELLAR 4 and the PGT202 trial demonstrated a statistically significant (p=0.004) survival advantage for women treated when compared to men They were also referring to some data mining they had done on the Stellar 3 and 4, but who knows how many subgroups they had analysed before they come up with that advantage. Clearly, FDA has not been impressed as they were not allowed to file on the subset without running a confirmatory trial. There may very well be a survival advantage for men compared to women in this indication, but most probably that will apply to all the taxanes and not only to Xyotax. Which means that it will still be difficult to prove superiority compared to paclitaxel et. al. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next